Shunichi Ishimura
Presidente en THANN Natural KK .
Origen de la red de primer grado Shunichi Ishimura.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Path Imaging KK
Path Imaging KK Medical SpecialtiesHealth Technology Path Imaging KK engages in the development, manufacture and sale of medical equipment. The company was founded in October 2014 and is headquartered in Hiromae, Japan.
3
| Holding Company | Medical Specialties | 3 |
Public Company | Industrial Machinery | 1 | |
THANN Natural KK
1
| Private Company | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Shunichi Ishimura a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Miscellaneous Commercial Services | Director/Board Member | |
METAREAL CORPORATION | Packaged Software | Director/Board Member | |
C.H.C. SYSTEM Co., Ltd. | Director/Board Member | ||
Kobe University Graduate School of Business Administration | College/University | Undergraduate Degree | |
J & I YK | Director/Board Member | ||
YES-fm KK | Comptroller/Controller/Auditor | ||
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Biotechnology | Director/Board Member | |
Development Association For Youthleaders | Director/Board Member |
Estadísticas
Internacional
Japón | 8 |
Alemania | 2 |
Sectorial
Commercial Services | 2 |
Technology Services | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Operativa
Director/Board Member | 11 |
President | 2 |
Comptroller/Controller/Auditor | 2 |
Founder | 1 |
Undergraduate Degree | 1 |
Las relaciones más conectadas
Insiders | |
---|---|
Hiroki Hidejima | 9 |
Masashi Sugawara | 2 |
Hideaki Kobayashi | 2 |
Tamotsu Sato | 1 |
- Bolsa de valores
- Insiders
- Shunichi Ishimura
- Conexiones Empresas